(주)유바이오로직스

{
  "address": "서울 강남구",
  "ceo_name": "백영옥, 허태영",
  "certificate": [
    {
      "cert_number": "20120101278",
      "changes": "",
      "disclosure_date": "2012-02-24",
      "first_cert_date": "2012-02-24",
      "no": "1",
      "type": "기술평가보증기업(기금)",
      "valid_period": "2012-02-24 ~ 2014-02-23"
    },
    {
      "cert_number": "20140300145",
      "changes": "",
      "disclosure_date": "2014-04-10",
      "first_cert_date": "2012-02-24",
      "no": "2",
      "type": "벤처투자유형",
      "valid_period": "2014-02-24 ~ 2016-02-23"
    },
    {
      "cert_number": "20160400240",
      "changes": "",
      "disclosure_date": "2016-03-08",
      "first_cert_date": "2012-02-24",
      "no": "3",
      "type": "연구개발유형",
      "valid_period": "2016-02-24 ~ 2018-02-23"
    },
    {
      "cert_number": "20180400466",
      "changes": "",
      "disclosure_date": "2018-03-15",
      "first_cert_date": "2012-02-24",
      "no": "4",
      "type": "연구개발유형",
      "valid_period": "2018-02-24 ~ 2020-02-23"
    },
    {
      "cert_number": "20200400642",
      "changes": "",
      "disclosure_date": "2020-04-02",
      "first_cert_date": "2012-02-24",
      "no": "5",
      "type": "연구개발유형",
      "valid_period": "2020-02-24 ~ 2022-02-23"
    },
    {
      "cert_number": "20220421020008",
      "changes": "",
      "disclosure_date": "2022-04-21",
      "first_cert_date": "2012-02-24",
      "no": "6",
      "type": "연구개발유형",
      "valid_period": "2022-02-24 ~ 2025-02-23"
    },
    {
      "cert_number": "20250311030109",
      "changes": "대표자",
      "disclosure_date": "2025-03-11",
      "first_cert_date": "2012-02-24",
      "no": "7",
      "type": "혁신성장유형",
      "valid_period": "2025-02-24 ~ 2028-02-23"
    }
  ],
  "company_name": "주식회사 유바이오로직스",
  "corp_no": "110111-*******",
  "financials": {
    "2022": {
      "capital_stock": 18222404000,
      "cost_of_sales": 30515151000,
      "current_assets": 40771911000,
      "current_liabilities": 24183392000,
      "gross_profit": 24595061000,
      "net_income": -2181710000,
      "net_income_bs": -2280954000,
      "non_current_assets": 119728897000,
      "non_current_liabilities": 17761878000,
      "non_operating_expenses": 5171284000,
      "non_operating_income": 4678535000,
      "operating_profit": -1688961000,
      "revenue": 55110211000,
      "sga_expenses": 26284022000,
      "total_assets": 160500808000,
      "total_equity": 118555538000,
      "total_liabilities": 41945270000
    },
    "2023": {
      "capital_stock": 18227404000,
      "cost_of_sales": 35326733000,
      "current_assets": 41727902000,
      "current_liabilities": 24899768000,
      "gross_profit": 33267345000,
      "net_income": -12413558000,
      "net_income_bs": -13158594000,
      "non_current_assets": 110147725000,
      "non_current_liabilities": 20917871000,
      "non_operating_expenses": 24765097000,
      "non_operating_income": 3568053000,
      "operating_profit": 8783486000,
      "revenue": 68594078000,
      "sga_expenses": 24483859000,
      "total_assets": 151875627000,
      "total_equity": 106057988000,
      "total_liabilities": 45817639000
    }
  },
  "industry": "합성의약품 및 기타 완제 의약품 제조업",
  "investment": [
    {
      "amount": "1,859,990,000",
      "changes": "1,859,990,000",
      "date": "2013-11-29"
    }
  ],
  "main_products": "경구용 콜레라 백신,바이오의약품 제조,수탁 연구",
  "phone": "02-572-****",
  "years": [
    2023,
    2022
  ]
}